Recommendation of the President – Fabhalta (iptacopan)

On 17 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 45/2025 on the appraisal of drug Fabhalta (iptacopan) under drug program B.96 “Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 D59.5)”

Publication in Public Information Bulletin (BIP) >>